COYA - Company ID 0001835022
The table below shows Coya Therapeutics, Inc.'s income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $7.95M | $3.55M | $6.00M | $0.00 | - |
| Cost of revenue | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| R&D | - | - | - | - | - |
| SG&A | $11.45M | $8.89M | $7.83M | $4.85M | $2.31M |
Coya Therapeutics, Inc. reported annual revenue of $7.95M for fiscal year 2025. That is up 123.6% from $3.55M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Operating income |
| -$22.56M |
| -$17.25M |
| -$7.90M |
| -$9.81M |
| -$4.87M |
| Income tax | $3.09K | -$720.29K | $723.85K | $0.00 | - |
| Net income | -$21.23M | -$14.88M | -$7.99M | -$12.24M | -$4.89M |
| EPS (diluted) | -$1.27 | -$0.98 | -$0.79 | -$4.73 | -$1.89 |